Detail
| LncRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 Sequence |
| Ensembl | ENSG00000177640 |
| RefSeq | NR_026939 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | malignant melanoma |
| ICD-0-3 | M8720/3 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | MM tissues, malignant melanoma cell lines (A375, A2058 and HTB63) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 acted as a molecular sponge for miR-18a-5p and RUNX1 was a target gene of miR-18a-5p. Moreover, CASC2 overexpression promoted the expression of RUNX1, while upregulated miR-18a-5p significantly reversed the effect of CASC2 on RUNX1 level.Upregulated CASC2 may inhibit cell proliferation, migration and invasion through regulating miR-18a-5p and its target gene RUNX1 in MM. |
| Pubmed ID | 29422114 |
| Year | 2018 |
| Title | Upregulated lncRNA CASC2 may inhibit malignant melanoma development through regulating miR-18a-5p/RUNX1. |
| External Links |
| Links for CASC2 | GenBank HGNC lncrnadb Noncode |
| Links for malignant melanoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.